Compare · DYN vs PEPG
DYN vs PEPG
Side-by-side comparison of Dyne Therapeutics Inc. (DYN) and PepGen Inc. (PEPG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DYN and PEPG operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- DYN is the larger of the two at $3.00B, about 8.1x PEPG ($370.4M).
- Over the past year, DYN is down 20.3% and PEPG is down 22.8% - DYN leads by 2.5 points.
- DYN has been more active in the news (13 items in the past 4 weeks vs 12 for PEPG).
- DYN has more recent analyst coverage (24 ratings vs 6 for PEPG).
- Company
- Dyne Therapeutics Inc.
- PepGen Inc.
- Price
- -
- -
- Market cap
- $3.00B
- $370.4M
- 1M return
- -0.34%
- +44.14%
- 1Y return
- -20.30%
- -22.84%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2022
- News (4w)
- 13
- 12
- Recent ratings
- 24
- 6
Dyne Therapeutics Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Latest DYN
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Commercial Officer Friedl-Naderer Johanna sold $3,885 worth of shares (231 units at $16.82) as part of a pre-agreed trading plan, decreasing direct ownership by 0.15% to 152,666 units (SEC Form 4) to cover taxes
- Head of R&D and CMO Kerr Douglas sold $43,799 worth of shares (2,604 units at $16.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 167,960 units (SEC Form 4) (for tax liability)
- CEO & President Cox John sold $92,729 worth of shares (5,513 units at $16.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 351,994 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Lucera Erick sold $33,489 worth of shares (1,991 units at $16.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 117,775 units (SEC Form 4) (withholding tax)
- SEC Form SCHEDULE 13G filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- Dyne Therapeutics to Participate in Upcoming Investor Conference
- Dyne Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest PEPG
- Amendment: SEC Form SCHEDULE 13D/A filed by PepGen Inc.
- Director Ra Capital Management, L.P. bought $43,125,000 worth of shares (8,625,000 units at $5.00) (SEC Form 4)
- PepGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by PepGen Inc.
- PepGen Announces Pricing of $125 Million Public Offering
- SEC Form 424B5 filed by PepGen Inc.
- PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
- PepGen upgraded by BofA Securities with a new price target
- PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by PepGen Inc.